Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Dexcom (DXCM) over the last 16 years, with Q4 2025 value amounting to -$10.1 million.

  • Dexcom's Change in Accured Expenses rose 4950.0% to -$10.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $347.0 million, marking a year-over-year increase of 6391.12%. This contributed to the annual value of $347.0 million for FY2025, which is 6391.12% up from last year.
  • Per Dexcom's latest filing, its Change in Accured Expenses stood at -$10.1 million for Q4 2025, which was up 4950.0% from -$2.3 million recorded in Q3 2025.
  • Dexcom's Change in Accured Expenses' 5-year high stood at $234.0 million during Q2 2025, with a 5-year trough of -$70.9 million in Q4 2021.
  • Moreover, its 5-year median value for Change in Accured Expenses was $62.9 million (2022), whereas its average is $68.9 million.
  • As far as peak fluctuations go, Dexcom's Change in Accured Expenses plummeted by 20441.83% in 2021, and later skyrocketed by 34776.47% in 2023.
  • Dexcom's Change in Accured Expenses (Quarter) stood at -$70.9 million in 2021, then skyrocketed by 274.61% to $123.8 million in 2022, then tumbled by 124.23% to -$30.0 million in 2023, then surged by 33.33% to -$20.0 million in 2024, then soared by 49.5% to -$10.1 million in 2025.
  • Its Change in Accured Expenses stands at -$10.1 million for Q4 2025, versus -$2.3 million for Q3 2025 and $234.0 million for Q2 2025.